Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1413 participants.
Also called NCT01719003
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,413 participants
- Registry
-
NCT01719003 -
2010-021375-92
-
- Other papers using this trial's data
- Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Brazil, Canada, Czechia, Egypt, France, Germany, Guatemala, Lebanon, Malaysia, Mexico, Peru, Philippines, Russia, Serbia, South Korea, Spain, Taiwan, Thailand, Türkiye, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01719003. Randomized; double masking; primary purpose treatment. Start 2012-10 (registry gives no type); primary completion 2014-11 (actual). Results posted on 2016-02-19.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Condition
- Hyperglycemia
- Intervention (Drug)
- Metformin 500 mg bid
- Intervention (Drug)
- Metformin 1000 mg bid
- Intervention (Drug)
- Empagliflozin low dose qd
- Intervention (Drug)
- Empagliflozin high dose qd
- Intervention (Drug)
- Empagliflozin low dose bid
- Intervention (Drug)
- Metformin 500 mg bid
- Intervention (Drug)
- Empagliflozin high dose bid
- Intervention (Drug)
- Empagliflozin low dose bid
- Intervention (Drug)
- Metformin 1000 mg bid
- Intervention (Drug)
- Metformin 500 mg bid
- Intervention (Drug)
- Metformin 1000 mg bid
- Intervention (Drug)
- Empagliflozin high dose bid
- Intervention (Drug)
- Metformin 1000 mg bid
- Intervention (Drug)
- Empagliflozin high dose bid
- Lead sponsor
- Boehringer Ingelheim
- Collaborator
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct01719003- Content hash
76c08d371e5fe0f584304524844563aed91fdbc8582dd85a03b744e23ca4ad21